{"id":"W2939222610","doi":"10.1056/nejmoa1811744","title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5996,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University of British Columbia","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Type 2 diabetes; Diabetes mellitus; Diabetic nephropathy; Nephropathy; Dapagliflozin; Internal medicine; Clinical trial; Type 2 Diabetes Mellitus; Endocrinology; Intensive care medicine; Pharmacology; Urology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}